Barclays’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-1,306,377
| Closed | -$23.5M | – | 5843 |
|
|
2020
Q2 | $23.5M | Buy |
1,306,377
+1,186,891
| +993% | +$16.5M | 0.02% | 579 |
|
|
2020
Q1 | $851K | Sell |
119,486
-56,406
| -32% | -$704K | ﹤0.01% | 3118 |
|
|
2019
Q4 | $4.2M | Buy |
175,892
+61,692
| +54% | +$1.7M | ﹤0.01% | 2199 |
|
|
2019
Q3 | $3.06M | Buy |
114,200
+56,603
| +98% | +$1.59M | ﹤0.01% | 2368 |
|
|
2019
Q2 | $1.56M | Buy |
57,597
+34,197
| +146% | +$1.07M | ﹤0.01% | 3197 |
|
|
2019
Q1 | $812K | Buy |
23,400
+1,480
| +7% | +$42.7K | ﹤0.01% | 3634 |
|
|
2018
Q4 | $428K | Sell |
21,920
-34,907
| -61% | -$718K | ﹤0.01% | 3943 |
|
|
2018
Q3 | $1.51M | Buy |
56,827
+39,050
| +220% | +$1.27M | ﹤0.01% | 3221 |
|
|
2018
Q2 | $671K | Sell |
17,777
-221,323
| -93% | -$8.47M | ﹤0.01% | 3672 |
|
|
2018
Q1 | $7.81M | Buy |
239,100
+151,666
| +173% | +$6.66M | 0.01% | 1327 |
|
|
2017
Q4 | $4.26M | Sell |
87,434
-2,128
| -2% | -$108K | ﹤0.01% | 1793 |
|
|
2017
Q3 | $4.84M | Sell |
89,562
-31,166
| -26% | -$1.83M | 0.01% | 1553 |
|
|
2017
Q2 | $6.78M | Buy |
120,728
+33,965
| +39% | +$1.36M | 0.01% | 1243 |
|
|
2017
Q1 | $3.4M | Buy |
86,763
+58,444
| +206% | +$1.86M | ﹤0.01% | 1616 |
|
|
2016
Q4 | $636K | Buy |
28,319
+17,219
| +155% | +$336K | ﹤0.01% | 3155 |
|
|
2016
Q3 | $251K | Sell |
11,100
-26,565
| -71% | -$624K | ﹤0.01% | 3779 |
|
|
2016
Q2 | $889K | Buy |
37,665
+30,086
| +397% | +$743K | ﹤0.01% | 2718 |
|
|
2016
Q1 | $152K | Buy |
7,579
+1,661
| +28% | +$52.7K | ﹤0.01% | 4052 |
|
|
2015
Q4 | $303K | Sell |
5,918
-13,733
| -70% | -$666K | ﹤0.01% | 3583 |
|
|
2015
Q3 | $825K | Buy |
19,651
+14,934
| +317% | +$721K | ﹤0.01% | 2912 |
|
|
2015
Q2 | $212K | Buy |
4,717
+2,899
| +159% | +$117K | ﹤0.01% | 4106 |
|
|
2015
Q1 | $68K | Sell |
1,818
-4,338
| -70% | -$149K | ﹤0.01% | 5093 |
|
|
2014
Q4 | $173K | Sell |
6,156
-597
| -9% | -$16.6K | ﹤0.01% | 4766 |
|
|
2014
Q3 | $170K | Sell |
6,753
-4,684
| -41% | -$123K | ﹤0.01% | 4891 |
|
|
2014
Q2 | $331K | Buy |
11,437
+4,269
| +60% | +$103K | ﹤0.01% | 4368 |
|
|
2014
Q1 | $180K | Buy |
7,168
+5,598
| +357% | +$149K | ﹤0.01% | 4887 |
|
|
2013
Q4 | $40K | Buy |
1,570
+1,209
| +335% | +$29.4K | ﹤0.01% | 6341 |
|
|
2013
Q3 | $9K | Sell |
361
-147
| -29% | -$3.5K | ﹤0.01% | 6833 |
|
|
2013
Q2 | $12K | Buy |
+508
| New | +$10.1K | ﹤0.01% | 7068 |
|
Barclays's PTLA Position: Q3 2020 in Review
Barclays sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 1,306,377 shares — an estimated $23.5M sold.
Barclays first reported a position in PTLA in Q2 2013 and held it in 29 quarters. The position peaked at $23.5M in Q2 2020. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Barclays reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Barclays sold 1,306,377 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $23.5M.
- Barclays first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- Barclays's Portola Pharmaceuticals, Inc. position peaked at $23.5M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Barclays's 13F filing for Q3 2020, filed 12 Nov 2020.